Detalles de la búsqueda
1.
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Acta Oncol
; 63: 213-219, 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38647024
2.
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Future Oncol
; 18(23): 2593-2604, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35722877
3.
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients.
Eur Arch Otorhinolaryngol
; 278(3): 771-779, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656672
4.
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Tumori
; : 3008916241246659, 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623748
5.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
6.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
7.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
J Thorac Oncol
; 18(8): 1070-1081, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094664
8.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286305
9.
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Per Med
; 19(1): 51-66, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34873959
10.
Metastatic pheochromocytomas and paragangliomas: where are we?
Tumori
; 108(6): 526-540, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35593402
11.
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Clin Lung Cancer
; 23(1): e17-e28, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34334296
12.
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
Cancers (Basel)
; 14(2)2022 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053597
13.
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.
Front Oncol
; 12: 1078822, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36755856
14.
Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.
Melanoma Res
; 31(2): 178-180, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33492050
15.
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.
Target Oncol
; 16(4): 529-536, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34076798
16.
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
J Pers Med
; 11(5)2021 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34069851
17.
Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
Clin Lung Cancer
; 22(3): 161-169, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33618994
18.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Eur J Cancer
; 154: 21-29, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34225066
19.
Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report.
Tumori
; 106(6): NP41-NP45, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32066344
20.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Ther Adv Med Oncol
; 12: 1758835920970081, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33335565